---
title: "\"Profit Alert\" Tigermed forecasts a profit increase of 105%-204% last year"
description: "Tigermed expects its profit for the fiscal year 2025 to grow by 105%-204%, ranging from 830 million to 1.23 billion RMB. The company's disposal and income from non-current financial assets have signif"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/274177703.md"
published_at: "2026-01-29T16:01:45.000Z"
---

# "Profit Alert" Tigermed forecasts a profit increase of 105%-204% last year

> Tigermed expects its profit for the fiscal year 2025 to grow by 105%-204%, ranging from 830 million to 1.23 billion RMB. The company's disposal and income from non-current financial assets have significantly increased, with both the number and amount of new orders showing growth. The total net new orders for the year are expected to be between 9.5 billion and 10.5 billion RMB, and operating revenue is projected to be between 6.66 billion and 7.68 billion RMB, an increase of 1%-16%

Tigermed (03347.HK) issued a profit warning, expecting a profit between RMB 830 million and RMB 1.23 billion for the fiscal year 2025, an increase of 105%-204% compared to the previous year. During the year, the disposal and holding income of non-current financial assets held by the company significantly increased. At the same time, both the number and amount of new orders signed achieved good growth, with a net increase in orders for the year expected to be between RMB 9.5 billion and RMB 10.5 billion, compared to RMB 8.42 billion recorded in the previous year.

In 2025, operating revenue is expected to be between RMB 6.66 billion and RMB 7.68 billion, an increase of 1%-16%, returning to a growth trend

### Related Stocks

- [516500.CN - ChinaAMC CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/516500.CN.md)
- [516930.CN - Minsheng Royal CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/516930.CN.md)
- [159837.CN - E Fund CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159837.CN.md)
- [300347.CN - Tigermed](https://longbridge.com/en/quote/300347.CN.md)
- [516820.CN - Ping An CSI Medicine and Medical Device Innovation ETF](https://longbridge.com/en/quote/516820.CN.md)
- [03347.HK - TIGERMED](https://longbridge.com/en/quote/03347.HK.md)
- [159849.CN - China Merchants CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159849.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| CStone Wins Second UK Approval for Lung Cancer Drug Sugemalimab | CStone Pharmaceuticals has received UK approval for its lung cancer drug, sugemalimab, as a monotherapy for adult patien | [Link](https://longbridge.com/en/news/276549711.md) |
| Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | [Link](https://longbridge.com/en/news/276024005.md) |
| Bioceltix Gets GMP Certificate For Wroclaw Veterinary Medicine Facility | Bioceltix :SAID ON TUESDAY IT OBTAINED A GMP CERTIFICATE FOR ITS WROCLAW FACILITY FROM THE MAIN PHARMACEUTICAL INSPECTOR | [Link](https://longbridge.com/en/news/276203122.md) |
| CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | [Link](https://longbridge.com/en/news/276051793.md) |
| Sino Biopharm Wins China Nod for New Lung Cancer Use of PD-L1 Drug | Sino Biopharmaceutical has received Chinese regulatory approval for its PD-L1 inhibitor, benmelstobart, for use as maint | [Link](https://longbridge.com/en/news/276016059.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.